Cholesterol, HDL ; Cholesterol ; Lipoproteins, HDL

Humans ; Inflammation ; Lipoproteins, HDL ; blood ; chemistry

BACKGROUND AND OBJECTIVES: The clinical significance of statin-induced high-density lipoprotein cholesterol (HDL-C) changes is not well known. We investigated whether rosuvastatin-induced HDL-C changes can influence the anti-oxidative action of high-density lipoprotein particle. SUBJECTS AND METHODS: A total of 240 patients with stable ischemic heart disease were studied. Anti-oxidative property was assessed by paraoxonase 1 (PON1) activity. We compared the lipid profile and PON1 activity at baseline and at 8 weeks after rosuvastatin 10 mg treatment. RESULTS: Rosuvastatin treatment increased the mean HDL-C concentration by 1.9±9.2 mg/dL (6.4±21.4%). HDL-C increased in 138 patients (57.5%), but decreased in 102 patients (42.5%) after statin treatment. PON1 activity increased to 19.1% in all patients. In both, the patients with increased HDL-C and with decreased HDL-C, PON1 activity significantly increased after rosuvastatin treatment (+19.3% in increased HDL-C responder; p=0.018, +18.8% in decreased HDL-C responder; p=0.045 by paired t-test). Baseline PON1 activity modestly correlated with HDL-C levels (r=0.248, p=0.009); however, the PON1 activity evaluated during the course of the treatment did not correlate with HDL-C levels (r=0.153, p=0.075). CONCLUSION: Rosuvastatin treatment improved the anti-oxidative properties as assessed by PON1 activity, regardless of on-treatment HDL-C levels, in patients with stable ischemic heart disease.
Aryldialkylphosphatase ; Cholesterol ; Cholesterol, HDL* ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Lipoproteins ; Lipoproteins, HDL ; Myocardial Ischemia* ; Rosuvastatin Calcium*

Cardiovascular Diseases ; Cholesterol, HDL ; Cholesterol, LDL ; Humans ; Lipoproteins, HDL ; Risk Factors

OBJECTIVES: To investigate the level and significance of serum γ-glutamyl transferase-to-platelet ratio (GPR) and monocyte count to high-density lipoprotein ratio (MHR) in patients with essential hypertension (EH) and unstable angina (UA). METHODS: A total of 218 patients with coronary angiography aged ≥60 years, who were admitted to the EH hospital of the Department of Cardiac Medicine, Affiliated Hospital of Chengde Medical College, were selected from September 2018 to September 2019. They were divided into an EH+UA group ( RESULTS: Compared with the control group, patients in the EH+UA group and the EH group had higher body mass index (BMI), tyiglyceride (TG), GPR, and MHR, and lower high-density lipoprotein-cholesterol (HDL-C) (all CONCLUSIONS There is a correlation between GPR, MHR and EH combined with UA pectoris, and the combined detection of the two indicators has adjuvant diagnostic value for elderly EH combined with UA.
Aged ; Angina, Unstable ; Cholesterol, HDL ; Coronary Angiography ; Essential Hypertension ; Humans ; Lipoproteins, HDL ; Monocytes

High density lipoprotein (HDL) is an important biochemical index of clinical cardiovascular disease. Many new studies have demonstrated abnormalities of plasma HDL subfractions in patients with this disease,and their clinical significance is greater than the overall abnormalities of HDL. Therefore,the HDL subfraction as an important factor in cardiovascular disease has attracted extensive research and attention. This article summarizes current research on HDL subfractions,their measurements and their relationships with atherosclerosis and coronary artery disease.
Humans ; Cardiovascular Diseases ; Clinical Relevance ; Cholesterol, HDL ; Lipoproteins, HDL ; Coronary Artery Disease

High density lipoprotein (HDL) is an important biochemical index of clinical cardiovascular disease. Many new studies have demonstrated abnormalities of plasma HDL subfractions in patients with this disease,and their clinical significance is greater than the overall abnormalities of HDL. Therefore,the HDL subfraction as an important factor in cardiovascular disease has attracted extensive research and attention. This article summarizes current research on HDL subfractions,their measurements and their relationships with atherosclerosis and coronary artery disease.
Humans ; Cardiovascular Diseases ; Clinical Relevance ; Cholesterol, HDL ; Lipoproteins, HDL ; Coronary Artery Disease

Lipoprotein lipase (LPL) is known to be attached to the luminal surface of vascular endothelial cells in a complex with membrane-bound heparan sulfate, and released into blood stream by heparin. LPL that catalyzes hydrolysis of triglyceride (TGL) on chylomicron and VLDL into two fatty acids and monoacylglycerol, is also implicated to participate in an enhancement of cholesterol uptake by arterial endothelial cells in vitro. But little is known about the LPL-mediated cholesterol uptake in physiological state. In this study, changes in blood lipid composition and levels of lipoproteins were determined after the injection of heparin in human. The level of LPL in plasma was increased from 0 to 11 mU/ml within 30-40 min post-heparin administration and decreased to the basal level within 2 h. The level of TGL in plasma decreased from 70 mg/dl to 20 mg/dl within 1 h and gradually increased to 80 mg/dl within 4 h. However the level of total cholesterol in plasma remained at 140 mg/dl during an experimental period of 4 h. Analysis of Lipoproteins in plasma by NaBr density gradient ultracentrifugation showed that the level of VLDL decreased from 50 mg/dl to 10 mg/dl within 1-2 h and returned to normal plasm level at 4 h. However there were no significant changes in the level of LDL and HDL. These results suggest that, at least, in normo-lipidemic subjects, increased free plasm LPL acts primarily on VLDL and failed to show any significant uptake of cholesterol-rich lipoproteins in human.
Adult ; Cholesterol/blood ; Heparin/pharmacology* ; Heparin/administration & dosage ; Human ; Immunoblotting ; Lipoprotein Lipase/blood* ; Lipoproteins/blood* ; Lipoproteins, HDL/blood ; Lipoproteins, LDL/blood ; Lipoproteins, VLDL/blood ; Triglycerides/blood

Epidemiological data clearly show the existence of a strong inverse correlation between plasma high-density lipoprotein cholesterol (HDL-C) concentrations and the incidence of coronary heart disease. This relation is explained by a number of atheroprotective properties of HDL, first of all the ability to promote macrophage cholesterol transport. HDL are highly heterogeneous and are continuously remodeled in plasma thanks to the action of a number of proteins and enzymes. Among them, lecithin:cholesterol acyltransferase (LCAT) plays a crucial role, being the only enzyme able to esterify cholesterol within lipoproteins. LCAT is synthetized by the liver and it has been thought to play a major role in reverse cholesterol transport and in atheroprotection. However, data from animal studies, as well as human studies, have shown contradictory results. Increased LCAT concentrations are associated with increased HDL-C levels but not necessarily with atheroprotection. On the other side, decreased LCAT concentration and activity are associated with decreased HDL-C levels but not with increased atherosclerosis. These contradictory results confirm that HDL-C levels per se do not represent the functionality of the HDL system.
Animals ; Atherosclerosis* ; Cholesterol* ; Coronary Disease ; Humans ; Incidence ; Lecithins* ; Lipoproteins* ; Lipoproteins, HDL ; Liver ; Macrophages ; Plasma ; Sterol O-Acyltransferase*

BACKGROUND: Psoriasis is a chronic inflammatory disease that also predisposes patients to metabolic syndrome and its components, most prevalent of which is hyperlipidemia. Statins are well-known cholesterol-lowering agents, which recently have been shown to have immunomodulatory and anti-inflamamtory effects.
OBJECTIVES: To determine the efficacy of simvastatin in the treatment of chronic plaque type psoriasis through the evaluation of Psoriasis Area and Severity Index (PASI), Physician Global Assessment Scores (PGA) and Dermatology Life Quality Index (DLQI), its effects on lipid profile and its adverse effects.
METHOD: Thirty (30) psoriasis patients, with lesions affecting at least 10% body surface area (BSA) were randomly assigned to take simvastatin 40mg/tablet or placebo tablet with application of 5% liquor carbonis detergens in petrolatum for both study groups. Patients were assessed at 4th and 8th week of treatment. Baseline data determined include patient's age, sex, previous medications, underlying diseases, weight, height, body mass index (BMI), PASI, PGA, DLQI, SGPT, SGOT and lipid profile. At 4th and 8th week of treatment, PASI, PGA, DLQI, SGPT, SGOT were obtained with addition of lipid profile, weight, height, and BMI at 8th week. The adverse reactions were also determined.
RESULTS: At 4th week of treatment, 80% in the simvastatin group demonstrated moderate improvement (based on 51-74% PASI score reduction) and 20% had mild improvement (PASI 25-50), while 40% in the placebo group showed mild improvement and 60% had no response to treatment (PASI<25). At 8th week of treatment, 66.7% in the simvastatin group had marked improvement (PASI ?75), 26.7% moderate improvement, and 6.65% mild improvement, while only 6.7% in the placebo group showed marked improvement, 13.3% moderate improvement, 60% mild improvement, and 20% with no response to treatment. The simvastatin group compared to placebo group demonstrated significant decrease in mean PGA scores at 4th and 8th week of treatment with p values of <0.001. The DLQI scores from the simvastatin group compared to the palcebo group showed significant decrease at 4th (p=0.01) and 8th week of treatment (p<0.001). Simvastatin patients at 8th week showed decline in total cholesterol (p<0.00001), triglycerides (p<0.05), low-density lipoprotein (p=0.05) while the high-density lipoprotein had significantly increased (p=0.05). The placebo group did not show any change in total cholesterol (p=0.22), low-density lipoprotein (p=0.60), triglycerides (p=0.44), and high-density lipoprotein (p=0.47). There were no adverse reactions noted due to simvastatin.
CONCLUSION: This randomized controlled trial showed that daily intake of 40 mg simvastatin was effective in the treatment of chronic plaque type psoriasis based on PASI,PGA and DLQI.

Human ; Male ; Female ; Aged ; Middle Aged ; Adult ; Young Adult ; Hyperlipidemias ; Lipoproteins, Hdl ; Lipoproteins, Ldl ; Petrolatum ; Psoriasis ; Simvastatin ; Triglycerides